Altimmune to present new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in a late-breaking presentation at the liver meeting® 2023

Gaithersburg, md., oct. 25, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week phase 1b randomized, placebo-controlled study in subjects with non-alcoholic fatty liver disease (nafld) will be presented in a late-breaking poster presentation at the liver meeting® 2023 of the american association for the study of liver diseases (aasld) in boston, ma (november 10-14, 2023). pemvidutide is a novel, investigational, peptide-based glp-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (nash).
ALT Ratings Summary
ALT Quant Ranking